Andere Sprachen Cerevel Therapeutics Holdings, Inc.

Aktien

A2QF3L

US15678U1280

CERE

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 17.05.2024			% 5 Tage	% 1. Jan.
42,1 ^USD	-0,59 %		-0,21 %	-0,71 %

14.05.	Cerevel Therapeutics Holdings Insider verkaufte Aktien im Wert von $2.105.125, laut einer aktuellen SEC Einreichung	MT
08.05.	Cerevel Therapeutics Holdings, Inc. meldet Ergebnis für das erste Quartal zum 31. März 2024	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Cerevel Therapeutics Holdings Insider Sold Shares Worth $2,105,125, According to a Recent SEC Filing	14.05.
Cerevel Therapeutics Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	08.05.
Cerevel Therapeutics Announces Positive Topline Results for Tavapadon in Phase 3 Adjunctive Trial for People Living with Parkinson's Disease	19.04.
Sector Update: Health Care Stocks Mixed Pre-Bell Thursday	18.04.
Cerevel Therapeutics' Potential Parkinson's Treatment Meets Primary Endpoint in Phase 3 Study	18.04.
Cerevel Therapeutics' Parkinson's disease drug meets main goal in late-stage study	18.04.
Cerevel Therapeutics Announces Positive Topline Results for Tavapadon in Phase 3 Adjunctive Trial for People Living with Parkinson’s Disease	18.04.
Cerevel Therapeutics Announces Positive Topline Results for Tavapadon in Phase 3 Adjunctive Trial for People Living with Parkinson?s Disease	18.04.
Actinogen Medical Notifies of Errors on M&A Slide in Recent Presentation	25.03.
Cerevel Therapeutics Holdings Insider Sold Shares Worth $2,057,890, According to a Recent SEC Filing	04.03.
Cerevel Therapeutics Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	27.02.
Sector Update: Health Care Stocks Gain Late Afternoon	22.02.
AbbVie Plans $13 Billion Bond Sale to Fund Acquisitions	22.02.
Phew! The party continues!	22.02.
AbbVie eyes selling at least $13 bln of bonds to fund M&A, Bloomberg reports	22.02.
North American Morning Briefing : Stock Futures -2-	21.02.
AbbVie CEO to Retire; COO Robert Michael Named Successor	20.02.
BioPharma Credit gets USD50.6 million from Abbvie's ImmunoGen purchase	13.02.
AbbVie Completes $10.1 Billion Acquisition of ImmunoGen, Lowers Q1 Adjusted EPS Guidance	12.02.
AbbVie 4Q Sales Lower as Himura Revenue Sinks	02.02.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Cerevel Therapeutics Holdings, Inc.

Aktien

A2QF3L

US15678U1280

CERE

Andere Sprachen

Filter